Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories ends day lower
Dr Reddy’s launches oral semaglutide in India
Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This launch expands access to advanced diabetes care. Dr Reddys is the second Indian company to introduce oral semaglutide domestically. The company is committed to reliable supply and consistent quality for Indian patients.
Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda In India
Dr Reddy's Laboratories
Stocks to Watch for May 21: Aditya Birla Capital, Dr Reddy's Lab, Jubilant Food, Bosch India and more
From Dr Reddy's Laboratories announcing the launch of its oral semaglutide biosimilar in India under the brand name Obeda to Whirlpool of India Ltd reporting a 32.7% year-on-year decline in net profit Q4, here are some stocks to track ahead of Thursday trading session.
Dr Reddy's launches oral semaglutide biosimilar Obeda in India
Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This innovative treatment offers patients the ease of a once-daily oral dosage, available in various strengths to effectively enhance glycaemic control. Dr.
Dr Reddy’s launches oral semaglutide biosimilar Obeda for type 2 diabetes in India
Shares of Dr Reddy's Laboratories Ltd ended at ₹1,320.00, down by ₹13.95, or 1.05%, on the BSE.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories reports solid trading activity
Dr. Reddy's launches generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on 28 April 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy's readiness to ensure patient access following approval.
Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada
Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providing treatment for type 2 diabetes. Canada is the first G7 nation to approve this medication. The launch follows a recent introduction in India. Dr Reddy's aims to expand access to these therapies globally.
Dr Reddy's Laboratories launches generic semaglutide injection in Canada
Dr Reddy's said it is among the first to introduce a generic semaglutide injection in the Canadian market after it received the Notice of Compliance (NOC) from Health Canada on April 28, 2026.
Dr Reddys Share Price Live Updates: Weekly returns for Dr. Reddy's Laboratories show a slight decrease
